BMY
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an alternative browser.
You should upgrade or use an alternative browser.
Bristol Meyers
- Thread starter ZZZzzzzzzz
- Start date
BMS Buys Celgene
In one of the biggest pharma takeovers ever, Bristol-Myers Squibb is paying $90 billion for Celgene, a company specializing in leukemia treatment. BMS thus far has a focus on solid tumors. Celgene CEO Mark Alles said the two companies had "complementary assets in different diseases and here we get to build on the scientific capabilities of both in a way that could not happen without this deal." Wall Street Journal
In one of the biggest pharma takeovers ever, Bristol-Myers Squibb is paying $90 billion for Celgene, a company specializing in leukemia treatment. BMS thus far has a focus on solid tumors. Celgene CEO Mark Alles said the two companies had "complementary assets in different diseases and here we get to build on the scientific capabilities of both in a way that could not happen without this deal." Wall Street Journal
BMS Buys Celgene
In one of the biggest pharma takeovers ever, Bristol-Myers Squibb is paying $90 billion for Celgene, a company specializing in leukemia treatment. BMS thus far has a focus on solid tumors. Celgene CEO Mark Alles said the two companies had "complementary assets in different diseases and here we get to build on the scientific capabilities of both in a way that could not happen without this deal." Wall Street Journal
WSJ got BMY ticker symbol wrong...